Skip to Content

Sanvar Approval Status

FDA Approved: No
Brand name: Sanvar
Generic name: vapreotide acetate
Company: Debiovision Inc.
Treatment for: Esophageal Varices with Bleeding

Sanvar (vapreotide acetate) is a somatostatin analogue in development for the treatment of acute esophageal variceal bleeding (EVB).

Development Status and FDA Approval Process for Sanvar

DateArticle
Nov  6, 2008Debiopharm Submits Response to the FDA for Sanvar (Debio 8609) for Esophageal Variceal Bleeding
Jan  5, 2005H3 Pharma Receives Approvable Letter from FDA for Sanvar for Esophageal Variceal Bleeding
Mar  2, 2004H3 Pharma Inc. Submits New Drug Application To FDA for Sanvar IR

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide